Mass spectrometry in precision medicine: Phenotypic measurements alongside pharmacogenomics

Clinical Chemistry

Volumn 62, Issue 1, 2016, Pages 70-76

  Clarke, Nigel J ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITUSSIVE AGENT; CLARITHROMYCIN; CODEINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ENDOXIFEN; ESTROGEN RECEPTOR; MORPHINE; MORPHINE GLUCURONIDE; NALOXONE; PROGESTERONE RECEPTOR; SULFOTRANSFERASE 1A1; TAMOXIFEN; VORICONAZOLE; DRUG;

ADULT; ANALGESIA; BODY COMPOSITION; BODY MASS; BREAST CANCER; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC PAIN; CONSCIOUSNESS DISORDER; COUGHING; CROHN DISEASE; DIET; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DISPOSITION; DRUG EXPOSURE; DRUG MONITORING; DRUG RESPONSE; DYSPNEA; ENVIRONMENTAL FACTOR; FATIGUE; FEVER; GENETIC DIFFERENCE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN GENOME; IMMUNOASSAY; IRRITABLE COLON; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEDICAL DECISION MAKING; METABOLITE; MIDDLE AGED; MYCOSIS; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; RECURRENCE RISK; REVIEW; CHEMISTRY; PHARMACOGENETICS;

DRUG MONITORING; HUMANS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; PRECISION MEDICINE;

EID: 84954467944     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.239475     Document Type: Review

References (32)

1. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011;3:111ra121.
2. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013;31:1806-14.
3. Stammer UM, Stuber F. Genetic factors in painandits treatment. Curr Opin Anaesthesiol 2007;20:478-84.
4. Kapur BM, Prateek KL, Shaw JLV. Pharmacogenetics of chronic pain management. Clin Biochem 2014;47:1169-87.
5. Pirmohamed M. Pharmacogenetics: past, present and future. Drug Discov Today 2011;852-61.
6. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286:2270-9.
7. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lötsch J, Roots I, Brockmöller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257-65.
8. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006;79:461-79.
9. Indiana University Department of Medicine. P450 drug interaction table: abbreviated "clinically relevant" table. http://medicine.iupui.edu/clinpharm/ddis/clinical-table/ (Accessed June 2015).
10. Dominques DS, Souza ID, Queiroz ME. Analysis of drugs in plasma samples from schizophrenic patients by column-switching liquid chromatography-tandem mass spectrometry with organic-inorganic hybrid cyanopropyl monolithic column. J Chromatogr B Analyt Biomed Life Sci 2015;993-994:26-35.
11. Zander J, Maier B, Suhr A, Zoller M, Frey L, Teupser D, Vogeser M. Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation. Clin Chem Lab Med 2015;53:781-91.
12. Kim HJ, Seo KA, Kim HM, Jeong ES, Ghim JL, Lee SH, et al. Simple and accurate quantitative analysis of 20 antituberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry. J Pharm Biomed Anal 2015;102:9-16.
13. Premaud A, Rousseau A, LeMeur Y, Lachatre G, Marguet P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 2004;26:609-19.
14. Tszyrsznic W, Borowiec A, Pawlowska E, Jazwiec R, Zochowska D, Bartlomiejczyk I, et al. Two rapid ultra performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay. J Chromatogr B Analyt Technol Biomed Life Sci 2013;928:9-15.
15. Kroenke K, Krebs E, Wu J, Bair MJ, Damush T, Chumbler N, et al. Stepped Care to Optimize Pain care Effectiveness (scope) trial study design and sample characteristics. Contemp Clin Trials 2013;34:270-81.
16. Bonica JJ. The need of a taxonomy. Pain 1979;6:247-8.
17. Eichelbaum M, Ingelman-Sunderberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006;57:119-37.
18. Jannetto PJ, Bratanow NC. Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring. Expert Opin Drug Metab Toxicol 2011;7:745-52.
19. van Schaik RHN. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008;77-98.
20. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825-9.
21. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-31.
22. Fernandez Mdel M, Willie SM, Kummer N, DiFazio V, Ruyssinckx E, Samyn N. Quantitative analysis of 26 opioids, cocaine, and their metabolites in human blood by ultra performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2013;35:510-21.
23. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrineresponsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012;104:441-51.
24. Del Re M, Michelucci A, Simi P, Danesi R. Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treat Rev 2012;38:442-50.
25. Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 2011;20:111-8.
26. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12:R64.
27. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011;89:718-25.
28. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol, 2010;10:1287-93.
29. Binkhorst L, Mathijssen RHJ, Jager A, van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6. Cancer Treat Rev 2015;41:289-99.
30. Jager NGI, Rosing H, Schellens JHM, Linn SC, Beijnen JH. Tamoxifen dose and serum concentrations of tamoxifen and six. Breast Cancer Res Treat 2014;143:477-83.
31. Binkhorst L, Mathijssen RHJ, Moghaddam-Helmantel IMG, de Bruijn P, van Gelder T, Wiemer EAC, Loos WJ. Quantification of tamoxifen and three of its phase-I metabolites in human plasma. J Pharm Biomed Anal 2011;56:1016-23.
32. Lu WJ, Xu C, Pei Z, Mayhoub AS, Cushman M, Flockhart DA. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat 2013;133:99-109.